Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license ...

Core Insights - 20/20 BioLabs is advancing its patented protein tumor marker (PTM) based, machine learning derived multi-cancer early detection (MCED) methodology, which shows promise for earlier stage cancer detection compared to circulating tumor DNA (ctDNA) based methods [1][4][5] Group 1: MCED Methodology and Findings - Recent studies indicate that protein biomarkers may effectively identify early-stage cancers, addressing the limitations of ctDNA tests, which often fail to detect cancer until it has progressed [3][4] - A large-scale ctDNA-based MCED study in the U.K. has highlighted the biological constraints of ctDNA as a first-line screening tool for early-stage cancers, emphasizing the need for alternative approaches [2][4] - 20/20 BioLabs' OneTest for Cancer has demonstrated detection rates for early-stage cancers as high as 50% for certain tumor types, such as pancreatic and ovarian cancers, in asymptomatic populations [6] Group 2: Validation and Support for Protein Biomarkers - A multicenter validation study published in Nature's Precision Oncology showed consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease [6] - A blinded validation study at MD Anderson Cancer Center reported that a protein-based multicancer test identified nearly 90% of early-stage lung cancers, indicating the effectiveness of protein tumor markers during early oncogenesis [6] Group 3: Strategic Approach and Future Directions - The company proposes a tiered approach to cancer screening, where protein-based tests like OneTest serve as the initial screening step, followed by ctDNA testing for individuals identified at mild risk [7] - The recent legislation passed by Congress to create a pathway for Medicare coverage of MCEDs starting in 2028 is seen as a significant advancement for cancer screening access [8] - 20/20 BioLabs is committed to building the evidence base for protein-based technologies and working with policymakers to ensure effective screening tools are available [8]

Core Viewpoint - 20/20 BioLabs has launched its OneTest for Longevity, a blood test that integrates inflammatory biomarkers, dietary habits, and scientific research to provide personalized health insights, utilizing IBM's watsonx.ai technology [1][2][3] Group 1: Product Launch and Features - The OneTest for Longevity solution calculates and displays an individual's risk of chronic diseases such as diabetes, dementia, and cardiovascular disease, offering personalized dietary recommendations based on biomarker levels [2] - The platform leverages IBM's advanced AI capabilities, including the Granite 4.0 foundation models and the Docling toolkit, to analyze nutritional research and deliver evidence-based health insights [3][6] - The test is available for purchase and is conducted in CLIA-licensed and CAP-accredited labs, although it has not sought FDA approval [3][7] Group 2: Partnerships and Technology - 20/20 BioLabs has partnered with DAISource to enhance its AI-enabled health solutions, aiming to improve public health through scalable and secure technology [3] - IBM's role is as an information technology provider, focusing on supporting enterprises with secure workloads in various sectors, including healthcare [4] Group 3: Company Background and Market Position - 20/20 BioLabs is an early market leader in laboratory-based blood tests for early detection and prevention of cancers and chronic diseases, with its stock listed on Nasdaq under the ticker symbol "AIDX" since February 19, 2026 [5][6] - The company also operates a Clinical Laboratory Innovation Accelerator (CLIAx) to assist overseas diagnostics startups in launching lab tests in the U.S. [8]

As filed with the U.S. Securities and Exchange Commission on January 21, 2026 Registration No. 333-292125 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither Road, Suite 235 Gaithersburg, MD 20877 ...

As filed with the U.S. Securities and Exchange Commission on December 12, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither ...